I don't know how many time people have to say this but biotech is a risky business and it usually comes down to a binary event. The outcome to which no-one knows and holding into trials results is a personal choice and their own responsibility.
The current board did the placement to keep control of the company. They have a plan and want to stay the course, a new bio asset would have most likely seen a re-rate to 10M MC.
The new comers have are part of the West Perth cowboys club that saw a cheap shell and took advantage. If they win they will most likely put in the latest "hot" asset, whether it be a medical pot grower, vanadium project or whatever. I would be more upset with the incumbents if I was you.
The best interests of shareholders are with the team that has the best strategy. Look into the new shareholders and see what their their past investments have been ...
FTT Price at posting:
0.3¢ Sentiment: None Disclosure: Not Held
